• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 8:01:32 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $ZOM alert in real time by email
    SC 13G/A 1 tm216512d1_sc13ga.htm SCHEDULE 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

     

    Zomedica Pharmaceuticals Corp.

    (Name of Issuer)

     

    Common Shares, without par value

    (Title of Class of Securities)

     

    98979F107

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 98979F107

    1

    NAME OF REPORTING PERSON:

    Jeffrey M. Rowe

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

    (a) ¨

    (b) ¨

     

    3

    SEC USE ONLY:

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    United States of America

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER:  1,532,980(1)

     

     

    6

    SHARED VOTING POWER:  11,120,000

     

     

    7

    SOLE DISPOSITIVE POWER:  1,532,980(1)

     

     

    8

    SHARED DISPOSITIVE POWER:  11,120,000

     

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:  12,652,980(1)

     

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

    2.2% (See Item 4 herein)

     

    12

    TYPE OF REPORTING PERSON:

    IN

     

     

    (1) Includes an option to purchase 350,000 common shares at an exercise price of $1.52 per share and an option to purchase 62,500 common shares at an exercise price of $0.19 per share.

     

    2

     

     

    1

    NAME OF REPORTING PERSON:

    Rowe Family GST Trust

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

    (a) ¨

    (b) ¨

     

    3

    SEC USE ONLY:

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Michigan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER:  0

     

     

    6

    SHARED VOTING POWER:  11,120,000

     

     

    7

    SOLE DISPOSITIVE POWER:  0

     

     

    8

    SHARED DISPOSITIVE POWER:  11,120,000

     

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:  11,120,000

     

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

    2.0% (See Item 4 herein)

     

    12

    TYPE OF REPORTING PERSON:

    OO

     

     

    END OF COVER PAGE

     

    3

     

     

    The Reporting Persons named in Item 2 below are hereby jointly filing this Amendment No. 2 to Schedule 13G (this “Statement”) because due to certain relationships among the Reporting Persons, such Reporting Persons may be deemed to beneficially own the same securities named in Item 4 below by one of the Reporting Persons. In accordance with Rule 13d-1(k)(1)(iii) promulgated pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Reporting Persons named in Item 2 below have executed a written agreement relating to the joint filing of this Statement (the “Joint Filing Agreement”), a copy of which is attached hereto as Exhibit 1.

     

    Item 1.(a)Name of Issuer.

     

    Zomedica Pharmaceuticals Corp.

     

     (b)Address of issuer’s principal executive offices.

     

    100 Phoenix Drive, Suite 125, Ann Arbor, Michigan 48108

     

    Item 2.(a)Name of persons filing (collectively, the “Reporting Persons”).

     

    (i)                 Jeffrey M. Rowe

    (ii)                Rowe Family GST Trust (the “GST Trust”)

     

     (b)Address of principal business office or, if none, residence.

     

    The address for both Mr. Rowe and the GST Trust is 3203 N. McKinley Rd, Flushing, Michigan 48433.

     

     (c)Citizenship or place of organization.

     

    Mr. Rowe is a citizen of the United States of America. The GST Trust was organized in the State of Michigan.

     

     (d)Title of class of securities.

     

    Common Shares, without par value (the “Common Shares”)

     

     (e)CUSIP No.

     

    98979F107

     

    Item 3.

     

    If this statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:

     

    (a)¨    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)¨    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)¨    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)¨    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e)¨    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).

     

    4

     

     

       (f)¨    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
         
    (g)¨    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
         
    (h)¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
         
    (i)¨    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
         
    (j)¨    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
         
    (k)¨    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution.

     

    Item 4. Ownership.

     

               

    (c)

    Number of Shares as to which the person has:

     

     

    Name

     

    (a)

    Amount
    Beneficially
    Owned

     

    (b)

    Percent
    of Class*

      Sole Power to
    Vote or to
    Direct the
    Vote
      Shared Power
    to Vote or to
    Direct the Vote
      Sole Power to
    Dispose or to
    Direct the
    Disposition of
      Shared Power
    to Dispose or to
    Direct the
    Disposition of
    Jeffrey M. Rowe   12,652,980(1)   2.2%   1,532,980(2)   11,120,000   1,532,980(2)   11,120,000
    Rowe Family GST Trust(3)  

    11,120,000

     

    2.0%

     

    0

     

    11,120,000

     

    0

     

    11,120,000

    (1)Includes the following: 275,000 shares held directly, 664,480 Common Shares held by the Jeffrey M. Rowe U/T/A dated November 5, 2004 (the “Living Trust”), for which Mr. Rowe serves as trustee, and 11,120,000 Common Shares held by the GST Trust. By reason of the provisions of Rule 13d-3 of the Act, Mr. Rowe may be deemed to beneficially own the shares beneficially owned by the GST Trust and the Living Trust. Mr. Rowe disclaims beneficial ownership of the securities held in both trusts except to his pecuniary interest therein and this report shall not be deemed as an admission of beneficial ownership of the reported securities. Also includes 181,000 Common Shares held in Mr. Rowe’s IRA, an option to purchase 350,000 Common Shares at an exercise price of $1.52 per share, and an option to purchase 62,500 Common Shares at an exercise price of $0.19 per share.
    (2)Includes 275,000 shares held directly, 664,480 Common Shares held in the Living Trust, 181,000 Common Shares held in Mr. Rowe’s IRA, an option to purchase 350,000 Common Shares at an exercise price of $1.52 per share, and an option to purchase 62,500 Common Shares at an exercise price of $0.19 per share.
    (3)The reporting person’s sister serves as trustee of the GST Trust, with Mr. Rowe’s oversight.

     

    * As of November 11, 2020 (based on 564,051,438 Common Shares outstanding as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020).

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    Not applicable.

     

    Exhibit Description
       
    1 Joint Filing Agreement dated February 8, 2018 (incorporated by reference to Exhibit 1 to Schedule 13G filed by the Reporting Persons with the SEC on February 14, 2018).

     

    5

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021  
       
    Jeffrey M. Rowe  
       
    /s/ Jeffrey M. Rowe  
    Jeffrey M. Rowe, individually  
       
    Rowe Family GST Trust  
       
    /s/ Michele Ramo  
    Name: Michele Ramo  
    Title: Trustee  

     

    6

     

    Get the next $ZOM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZOM

    DatePrice TargetRatingAnalyst
    1/6/2023$6.00Buy
    Dawson James
    More analyst ratings

    $ZOM
    Financials

    Live finance-specific insights

    See more
    • Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth

      ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2024."We are very pleased with our performance, highlighted by record third quarter revenue and a double-digit increase compared to last year, which demonstrates that the execution of our growth initiatives has continued to pay dividends. As expected, PulseVet® capital sales rebounded during the third quarter bolstered by a full-strength sales team in the U.S. and continued positive

      11/7/24 4:25:00 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET

      ANN ARBOR, MI / ACCESSWIRE / October 23, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its thirdquarter ended September 30, 2024. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Corp. Q3 2024 Financial Results Conference CallDate: Thursday, November 7, 2024Time: 4:30 p.m. Eastern TimeLive Call: +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (Internat

      10/23/24 3:00:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth

      Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024."We are pleased with the progress in the quarter, which represents the highest second quarter for the Company to date. We saw significant growth in our diagnostic product revenue, reflecting growing adoption of our TRUFORMA® and VETGuardian® products. We also enjoyed substantial growth in consumable products, reflecting the robust usage of ou

      8/14/24 4:05:00 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    SEC Filings

    See more
    • Zomedica Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zomedica Corp. (0001684144) (Filer)

      3/13/25 6:59:46 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 10-K filed by Zomedica Corp.

      10-K - Zomedica Corp. (0001684144) (Filer)

      3/13/25 4:03:40 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 25-NSE filed by Zomedica Corp.

      25-NSE - Zomedica Corp. (0001684144) (Subject)

      3/13/25 12:02:46 PM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

      4/A - Zomedica Corp. (0001684144) (Issuer)

      3/27/25 9:56:49 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/20/25 9:52:31 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Chief Financial Officer Jordan Scott bought $18,600 worth of shares (300,000 units at $0.06) (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/19/25 11:47:14 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ZOM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Dawson James initiated coverage on Zomedica Pharmaceuticals with a new price target

      Dawson James initiated coverage of Zomedica Pharmaceuticals with a rating of Buy and set a new price target of $6.00

      1/6/23 9:00:39 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Zomedica Corp. (0001684144) (Subject)

      2/16/21 8:01:32 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Leadership Updates

    Live Leadership Updates

    See more
    • Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

      Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025."Scott brings a broad range of skills and experience that will be increasingly important to us as we move forward," said Larry Heaton, Zomedica's Chief Executive Officer. We are excited to welcome him to the Zomedica team and look forward to leveraging his expertis

      12/19/24 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Appoints New Chief Financial Officer

      ANN ARBOR, MI / ACCESSWIRE / March 17, 2023 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023. Mr. Donato brings over 30 years of public and private company experience in a wide range of finance and business functions primarily in the human health sector, having held a number of senior positions from CFO, President and CEO, Executive Vice President, Senior Vice President, Vice President and Controller. Prior to joining Zomedica, Mr. Donato had a successful consulting

      3/17/23 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors

      ANN ARBOR, MI / ACCESSWIRE / August 23, 2022 / Zomedica Corp. (NYSE:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Pamela Nichols, DVM has been appointed to its Board of Directors and is joining the Audit and Governance committees.Dr. Nichols is the founder of six successful veterinary hospitals and dog boarding/daycare facilities. Her newest hospital is Animal Care Daybreak in South Jordan Utah, which opened in October of 2019. She earned her doctorate in veterinary medicine at Colorado State University in 1996 and her Canine Rehabilitation Practitioner (CCRP) certification in 2004. She

      8/23/22 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

      License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States.Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to

      1/7/25 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

      With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the di

      12/23/24 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

      Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025."Scott brings a broad range of skills and experience that will be increasingly important to us as we move forward," said Larry Heaton, Zomedica's Chief Executive Officer. We are excited to welcome him to the Zomedica team and look forward to leveraging his expertis

      12/19/24 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $ZOM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

      4/A - Zomedica Corp. (0001684144) (Issuer)

      3/27/25 9:56:49 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/20/25 9:52:31 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Chief Financial Officer Jordan Scott bought $18,600 worth of shares (300,000 units at $0.06) (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/19/25 11:47:14 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care